Opinion|Videos|July 22, 2024
Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging Results
Author(s)Tony Abraham, DO, MPA
Tony Abraham, DO, MPA, outlines the limitations of PSMA-PET imaging and discusses the importance of multidisciplinary care in overcoming challenges surrounding the interpretation and reporting of imaging results.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- In terms of using PSMA-PET imaging in the staging and monitoring of patients with prostate cancer, what are some challenges based on the use of analog vs digital cameras? What are some limitations of older cameras?
- What are some challenges surrounding the interpretation and reporting of PSMA-PET imaging results? Do you have tips for how the entire multidisciplinary care team can work together to ensure everyone is on the same page in terms of reporting/interpreting results and making treatment decisions?
Advertisement
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
5